medigraphic.com
Instituto Nacional de Salud Pública

2021, Number 5

<< Back Next >>

salud publica mex 2021; 63 (5)

Comportamiento epidemiológico de SARS-CoV-2 en población trabajadora afiliada al Instituto Mexicano del Seguro Social

Hernández-Ávila M, Vieyra-Romero W, Gutiérrez-Díaz H, Barros-Sierra D, Zepeda R, Segura-Sánchez C, Velasco R, Ramírez EA, Tamayo-Ortiz M, Borja-Aburto V, Rascón-Pacheco A, Barrientos-Gutiérrez T, Ortega-Álvarez M

Language: Spanish
References: 25
Page: 607-618
PDF size: 406.83 Kb.


ABSTRACT

Objective. To describe the behavior of SARS-CoV-2 epidemic among workers affiliated to the Mexican Social Security Institute. Materials and methods. We analyzed Short Term Disability Claims due to Respiratory Diseases (RD-STDC), associated hospitalizations and deaths (March 1 – December 31, 2020). We estimated the attack rate (AR) for SARS-CoV-2, and relative risks (RR) of TWD-RD, hospitalization and deaths. Results. 1 730 334 workers received at least one RD-STDC. AR was higher in women and in both sexes it was lower in ›60 years old. RR of hospitalization and death were higher in men and increased with age. Compared with RD-STDC of 2015-2019, the states of Durango, Tamaulipas and Nuevo Leon had a higher RR of RD-STDC than the rest of the country. Conclusions. The SARS-CoV-2 epidemic impacted IMSS-affiliated workers significantly. We observed a 4.6 fold excess in RD-STDC compared to the expected frequency and nearly 1 million SARS-CoV-2 cases in this population. Our data suggest that the RD-STDC system can be used as an additional resource for epidemiological surveillance of emerging diseases.


REFERENCES

  1. World Health Organization. COVID-19: cronología de la actuación de la OMS. Ginebra: WHO [citado enero 20, 2021]. Disponible en: https://www. who.int/es/news/item/27-04-2020-who-timeline---covid-19

  2. Center for Systems Science and Engineering. COVID-19 Map. Baltimore, MD: Johns Hopkins University and Medicine [citado enero 20, 2021]. Disponible en: https://coronavirus.jhu.edu/map.html

  3. Palacio Mejía LS, Wheatley-Fernández JL, Ordoñez-Hernández I, López- Ridaura R, Gatell-Ramírez HL, Hernández-Ávila M, Hernández-Ávila JE. Estimación del exceso de mortalidad por todas las causas durante la pandemia del Covid-19 en México. Salud Publica Mex. 2021;63(1):211-24. https://doi.org/10.21149/12225

  4. Berenguer J, Ryan P, Rodríguez-Baño J, Jarrín I, Carratalá J, Pachón J, et al. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. Clin Microbiol Infect. 2020;26(11):1525-36. https://doi.org/10.1016/j.cmi.2020.07.024

  5. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323(18):1775-

  6. https://doi.org/10.1001/jama.2020.4683 6. Gold J, Wong K, Szablewski C, Patel P, Rossow J, da Silva J, et al. Characteristics and clinical outcomes of adult patients hospitalized with COVID-19 — Georgia, March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(18):545-50. https://doi.org/10.15585/mmwr.mm6918e1

  7. Padilla-Raygoza N, Sandoval-Salazar C, Díaz-Becerril L-A, Beltrán-Campos V, Díaz-Martínez DA, Navarro-Olivos E, et al. Update of the evolution of SARS-CoV-2 infection, COVID-19, and mortality in Mexico until May 15, 2020: An ecological study. Int J Trop Dis Health. 2020;41(5):36-45. https://doi.org/10.9734/ijtdh/2020/v41i530277

  8. Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, Vargas-Vázquez A, Díaz-González A, Márquez-Salinas A, et al. Predicting mortality due to SARS-CoV-2: A mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico. MedRxiv. 2020. https://doi. org/10.1101/2020.04.20.20072223

  9. Friedman J, Calderón-Villarreal A, Bojorquez I, Vera-Hernández C, Schriger DL, Tovar-Hirashima E. Excess out-of-hospital mortality and declining oxygen saturation: The sentinel role of emergency medical services data in the COVID-19 Crisis in Tijuana, Mexico. Ann Emerg Med. 2020;76(4):413- 26. https://doi.org/10.1016/j.annemergmed.2020.07.035

  10. Suárez V, Suarez-Quezada M, Oros-Ruiz S, Ronquillo De Jesús E. Epidemiology of COVID-19 in Mexico: from the 27th of February to the 30th of April 2020. Rev Clin Esp. 2020;220(8):463-71. https://doi.org/10.1016/j. rce.2020.05.007

  11. Najera H, Ortega-Avila AG. Health and institutional risk factors of COVID-19 Mortality in Mexico, 2020. Am J Prev Med. 2021;60(4):471-7. https://doi.org/10.1016/j.amepre.2020.10.015

  12. Ortiz-Brizuela E, Villanueva-Reza M, González-Lara MF, Tamez-Torres KM, Román-Montes CM, Díaz-Mejía B, et al. Clinical and epidemiological characteristics of patients diagnosed with COVID-19 in a tertiary care center in Mexico City: A prospective cohort study. Rev Investig Clin. 2020;72(3):165-77. https://doi.org/10.24875/RIC.20000211

  13. Hernández-Ávila M, Vieyra-Romero W, Gutiérrez-Díaz H, Barros-Sierra D, Zepeda R, Segura-Sánchez C, et al. Material suplementario Comportamiento epidemiológico de SARS-CoV-2 en población trabajadora afiliada al Instituto Mexicano del Seguro Social, 1 marzo a 31 diciembre 2020. Figshare. 2021:1443125. https://doi.org/10.6084/M9.FIGSHARE.15086724.V2

  14. Instituto Mexicano del Seguro Social. Acercando el IMSS al Ciudadano. México: IMSS [citado enero 20, 2021]. Disponible en: http://www.imss. gob.mx/conoce-al-imss/informe-2019-2020

  15. Pérez-Cuevas R, Doubova SV, Wirtz VJ, Servan-Mori E, Dreser A, Hernández-Ávila M. Effects of the expansion of doctors’ offices adjacent to private pharmacies in Mexico: secondary data analysis of a national survey. BMJ. 2014;4(5):4669. https://doi.org/10.1136/bmjopen-2013-004669

  16. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13. https://doi.org/10.1016/S0140-6736(20)30211-7

  17. Klein S, Flanagan K. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626-38. https://doi.org/10.1038/nri.2016.90

  18. Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588:315-20. https://doi.org/10.1038/s41586-020-2700-3

  19. vom Steeg L, Klein S. SeXX Matters in infectious disease pathogenesis. PLOS Pathog. 2016;12(2):e1005374. https://doi.org/10.1371/journal. ppat.1005374

  20. Reynales-Shigematsu LM, Wipfli H, Samet J, Regalado-Pineda J, Hernández- Ávila M. Tobacco control in Mexico: A decade of progress and challenges. Salud Publica Mex. 2019;61(3):292-302. https://doi.org/10.21149/9360

  21. Instituto Mexicano del Seguro Social. Algoritmos interinos para la atención del COVID-19. México: Gobierno Federal, 2020. Disponible en: http://educacionensalud.imss.gob.mx/es/system/files/Algoritmos_interinos_ COVID19_CTEC.pdf

  22. Kerr C, Mistry D, Stuart R, Rosenfeld K, Hart G, Núñez R, et al. Controlling COVID-19 via test-trace-quarantine. MedRxiv. 2021. https://doi. org/10.1101/2020.07.15.20154765

  23. Nienhaus A, Hod R. COVID-19 among Health Workers in Germany and Malaysia. Int J Environ Res Public Health. 2020;17(13):4881. https://doi. org/10.3390/ijerph17134881

  24. Banerjee A, Pasea L, Harris S, Gonzalez-Izquierdo A, Torralbo A, Shallcross L, et al. Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study. Lancet. 2020;395(10238):1715-25. https:// doi.org/10.1016/S0140-6736(20)30854-0

  25. Instituto Nacional de Salud Pública. Tablero interactivo sobre COVID- 19. México: Gobierno Federal [citado mayo 22, 2021]. Disponible en: https://www.insp.mx/informacion-institucional-covid-19.html




2020     |     www.medigraphic.com